ClinicalTrials.gg
CompletedNCT05559476Updated Sep 24, 2024Results posted

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and FLU HD vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 46 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,029
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
8th of 17
1,029 · median 976
Started
2022
with 2 others
Phase 3
15 of 17
none open now
Registered
5th of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 8th largest by enrollment, is one of 3 that started in 2022, is one of 15 in phase 3, and was the 5th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus
  • High dose quadrivalent influenza vaccine
  • Immunogenicity
  • Safety
  • Reactogenicity
  • Adults aged 65 years and above
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol
  • A male or female ≥65 years of age at the time of the first study intervention administration.
  • Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.
  • Written or witnessed obtained from the participant prior to performance of any study-specific procedure.
  • Participants who are medically stable in the opinion of the investigator at the time of first vaccination. Participants with chronic stable medical conditions with or without specific treatment are allowed to participate in this study if considered by the investigator as medically stable.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination (no laboratory testing required).
  • History of any reaction or likely to be exacerbated by any component of the vaccines.
  • Hypersensitivity to latex.
  • History of Guillain Barré syndrome, or anaphylaxis.
  • Serious or unstable chronic illness.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Recurrent or un-controlled neurological disorders or seizures. Participants with medically-controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol (e.g. completion of diary cards, attend regular phone calls/study site visits).
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine or medical device) other than the study interventions during the period beginning 30 days before the first study vaccine administration, or planned use during the study period.
  • Administration of an influenza vaccine during the 6 months preceding the study FLU vaccine administration.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first study intervention administration and ending 30 days after the last study intervention administration.

Note: In case an emergency mass vaccination for an unforeseen public health threat (e.g.: a pandemic) is recommended and/or organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.

  • Previous vaccination with an RSV vaccine.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the first dose of study vaccine or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first study vaccination or planned administration during the study period. For , this will mean prednisone ≥20 mg/day, or equivalent. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device).

Other exclusions

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Planned move during the study conduct that prohibits participation until 1 month post-last vaccine administration.
  • Bedridden participants.
  • Participation of any study personnel or their immediate dependents, family, or household members.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,029 participants (actual)

Study arms

  • Experimental
    Co-Ad Group

    Participants received one dose of FLU-HD vaccine and one dose of RSVPreF3 OA vaccine, both doses administered at Day 1, and were followed until end of study.

    Biological: RSVPreF3 OA investigational vaccine · Biological: FLU HD vaccine

  • Active comparator
    Control Group

    Participants received one dose of FLU-HD vaccine at Day 1, followed by one dose of RSVPreF3 OA vaccine at Day 31, and were followed until the study end.

    Biological: RSVPreF3 OA investigational vaccine · Biological: FLU HD vaccine

Interventions

  • RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

  • BiologicalFLU HD vaccine

    FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).

06

What researchers measure

Primary outcomes

  1. RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)

    RSV-A neutralizing titers were given as group GMTs and expressed as Estimated Dilution 60 (ED60).

    Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)

  2. Hemagglutinin Inhibition (HI) Titers for 4 FLU Vaccine Strains Expressed as Group GMTs

    HI titers were assessed against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata strains.

    Time frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)

  3. RSV-B Neutralizing Titers Expressed as Group GMTs

    RSV-B neutralizing titers were given as group GMTs and expressed as Estimated Dilution 60 (ED60).

    Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)

Secondary outcomes

  1. HI Seroconversion Rate (SCR) for 4 FLU Vaccine Strains

    SCR for HI titers was defined as the percentage of participants who have either a HI predose titer less than (\<) 1:10 and a post-dose titer greater than or equal to (\>=) 1:40, or a pre-dose titer \>= 1:10 and at least a 4-fold increase in post-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

    Time frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)

  2. RSV-A Neutralizing Titers Expressed as Mean Geometric Increase (MGI)

    MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

    Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)

  3. RSV-B Neutralizing Titers Expressed as MGI

    MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

    Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)

  4. HI Titers for Each of the 4 FLU Vaccine Strains Expressed as GMT

    HI titers were assessed against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata strains. HI antibodies were expressed as GMTs, in titers.

    Time frame: At Day 1 and 1 month after FLU vaccine dose administration (Day 31 for both groups)

  5. HI Seroprotection Rate (SPR) for 4 FLU Vaccine Strains

    SPR for HI titers was defined as the percentage of participants with a serum HI titer \>= 1:40. The assessed Flu strains were: The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

    Time frame: At Day 1 and 1 month after FLU vaccine dose administration (Day 31 for both groups)

  6. HI Titers for 4 FLU Vaccine Strains, Expressed as MGI

    MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

    Time frame: At 1 month after the FLU vaccine dose administration (Day 31 for both groups)

  7. Percentage of Participants With Solicited Administration Site Events After Each Vaccine Dose Administration

    The solicited administration site events after vaccination included erythema, pain and swelling.

    Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination (administered on Day 1 and 31)

  8. Percentage of Participants Reporting Each Solicited Systemic Event After Each Vaccine Dose Administration

    The solicited systemic events after vaccination include arthralgia, fatigue, fever, headache and myalgia.

    Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination (administered on Day 1 and 31)

  9. Percentage of Participants Reporting Unsolicited Adverse Events (AEs)

    An unsolicited AEs is an AE that is not included in a list of solicited events using a participant diary. Unsolicited events must have been spontaneously communicated by a participant who signs the informed consent. Unsolicited AEs include both serious, non-serious AEs and potential immune-mediated diseases (pIMDs).

    Time frame: Within 30 days after vaccine administration (the day of vaccination and 29 subsequent days after vaccination)

  10. Percentage of Participants Reporting Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant.

    Time frame: From Day 1 up to study end (6 months after last vaccination - Month 6 for Co-Ad Group and Month 7 for Control group)

  11. Percentage of Participants Reporting Potential Immune-mediated Disease (pIMDs)

    pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. The investigator must exercise his/her medical/scientific judgment to determine whether other diseases have an autoimmune origin (i.e. pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and should also be recorded as a pIMD.

    Time frame: From Day 1 up to study end (6 months after last vaccination - Month 6 for Co-Ad Group and Month 7 for Control group)

07

Results

Posted Apr 4, 2024

Participant flow

1029 participants received at least one dose of the study intervention and were included in the exposed set.

Participant flow — Overall Study
MilestoneCo-Ad GroupControl Group
Started516513
Completed493485
Not completed2328
Withdrew: Adverse event20
Withdrew: Lost to follow-up1312
Withdrew: Consent withdrawal, not due to a (s)ae814
Withdrew: Other02

Outcome measures

PrimaryRSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)

RSV-A neutralizing titers were given as group GMTs and expressed as Estimated Dilution 60 (ED60).

Time frame:
At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
Reported as:
Geometric mean · Titers
RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)
TitersCo-Ad GroupControl Group
RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)5876.3 (5299.5 to 6515.9)6935.3 (6200.0 to 7757.9)
Statistical analysis
  • Co-Ad Group vs Control Group · Gmt ratio: 1.18 · 95% CI 1.03 to 1.35The comparison is done using the adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group, the age category as fixed effects and the pre-dose log-10 titer as covariate.
PrimaryHemagglutinin Inhibition (HI) Titers for 4 FLU Vaccine Strains Expressed as Group GMTs

HI titers were assessed against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata strains.

Time frame:
At 1 month after the FLU vaccine dose (Day 31 for both groups)
Reported as:
Geometric mean · Titers
Hemagglutinin Inhibition (HI) Titers for 4 FLU Vaccine Strains Expressed as Group GMTs
TitersCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N272.7 (64.1 to 82.5)72.3 (63.7 to 82.1)
Flu A/Victoria/2570/2019 H1N1189.9 (167.6 to 215.1)177.3 (156.4 to 200.9)
Flu B/Austria/1359417/2021 Victoria859.8 (805.8 to 917.5)820.9 (768.8 to 876.6)
Flu B/Phuket/3073/2013 Yamagata758.7 (699.1 to 823.4)703.4 (647.7 to 763.9)
Statistical analysis
  • Co-Ad Group vs Control Group · Gmt ratio: 0.99 · 95% CI 0.85 to 1.16The comparison was done using the adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group, the age category as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-Ad Group vs Control Group · Gmt ratio: 0.93 · 95% CI 0.80 to 1.09The comparison was done using the adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group, the age category as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-Ad Group vs Control Group · Gmt ratio: 0.95 · 95% CI 0.88 to 1.03The comparison was done using the adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group, the age category as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-Ad Group vs Control Group · Gmt ratio: 0.93 · 95% CI 0.84 to 1.02The comparison was done using the adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group, the age category as fixed effects and the pre-dose log-10 titer as covariate.
PrimaryRSV-B Neutralizing Titers Expressed as Group GMTs

RSV-B neutralizing titers were given as group GMTs and expressed as Estimated Dilution 60 (ED60).

Time frame:
At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
Reported as:
Geometric mean · Titers
RSV-B Neutralizing Titers Expressed as Group GMTs
TitersCo-Ad GroupControl Group
RSV-B Neutralizing Titers Expressed as Group GMTs8251.5 (7460.6 to 9126.3)8359.0 (7492.8 to 9325.3)
Statistical analysis
  • Co-Ad Group vs Control Group · Gmt ratio: 1.01 · 95% CI 0.89 to 1.15The comparison was done using the adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group, the age category as fixed effects and the pre-dose log-10 titer as covariate.
SecondaryHI Seroconversion Rate (SCR) for 4 FLU Vaccine Strains

SCR for HI titers was defined as the percentage of participants who have either a HI predose titer less than (\<) 1:10 and a post-dose titer greater than or equal to (\>=) 1:40, or a pre-dose titer \>= 1:10 and at least a 4-fold increase in post-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

Time frame:
At 1 month after the FLU vaccine dose (Day 31 for both groups)
Reported as:
Number · Percentage of participants
HI Seroconversion Rate (SCR) for 4 FLU Vaccine Strains
Percentage of participantsCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N259.2 (54.5 to 63.8)57.5 (52.7 to 62.2)
Flu A/Victoria/2570/2019 H1N150.9 (46.2 to 55.6)46.8 (42.0 to 51.6)
Flu B/Austria/1359417/2021 Victoria39.7 (35.2 to 44.3)31.1 (26.8 to 35.7)
Flu B/Phuket/3073/2013 Yamagata43.6 (39.0 to 48.3)37.7 (33.2 to 42.4)
Statistical analysis
  • Co-Ad Group vs Control Group · Difference of percentage: -1.71 · 95% CI -8.15 to 4.74
  • Co-Ad Group vs Control Group · Difference of percentage: -4.11 · 95% CI -10.67 to 2.48
  • Co-Ad Group vs Control Group · Difference of percentage: -8.56 · 95% CI -14.75 to -2.29
  • Co-Ad Group vs Control Group · Difference of percentage: -5.89 · 95% CI -12.28 to 0.56
SecondaryRSV-A Neutralizing Titers Expressed as Mean Geometric Increase (MGI)

MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

Time frame:
At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)
Reported as:
Geometric mean · Ratio
RSV-A Neutralizing Titers Expressed as Mean Geometric Increase (MGI)
RatioCo-Ad GroupControl Group
RSV-A Neutralizing Titers Expressed as Mean Geometric Increase (MGI)5.59 (5.02 to 6.23)6.75 (5.93 to 7.68)
SecondaryRSV-B Neutralizing Titers Expressed as MGI

MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

Time frame:
At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)
Reported as:
Geometric mean · Ratio
RSV-B Neutralizing Titers Expressed as MGI
RatioCo-Ad GroupControl Group
RSV-B Neutralizing Titers Expressed as MGI5.19 (4.69 to 5.75)5.29 (4.65 to 6.03)
SecondaryHI Titers for Each of the 4 FLU Vaccine Strains Expressed as GMT

HI titers were assessed against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata strains. HI antibodies were expressed as GMTs, in titers.

Time frame:
At Day 1 and 1 month after FLU vaccine dose administration (Day 31 for both groups)
Reported as:
Geometric mean · Titers
HI Titers for Each of the 4 FLU Vaccine Strains Expressed as GMT
TitersCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N2, Day 111.5 (10.5 to 12.7)12.6 (11.4 to 14.0)
Flu A/Darwin/6/2021 H3N2, Day 3171.8 (63.6 to 81.0)75.1 (66.7 to 84.4)
Flu A/Victoria/2570/2019 H1N1, Day 135.3 (31.2 to 40.1)41.9 (36.9 to 47.6)
Flu A/Victoria/2570/2019 H1N1, Day 31200.0 (178.7 to 223.8)194.7 (173.9 to 217.9)
Flu B/Austria/1359417/2021 Victoria, Day 1292.6 (270.6 to 316.4)308.5 (285.8 to 333.1)
Flu B/Austria/1359417/2021 Victoria, Day 31848.0 (799.7 to 899.2)818.3 (769.2 to 870.5)
Flu B/Phuket/3073/2013 Yamagata, Day 1239.2 (220.6 to 259.3)245.5 (226.1 to 266.5)
Flu B/Phuket/3073/2013 Yamagata, Day 31751.1 (698.9 to 807.2)699.6 (646.9 to 756.6)
SecondaryHI Seroprotection Rate (SPR) for 4 FLU Vaccine Strains

SPR for HI titers was defined as the percentage of participants with a serum HI titer \>= 1:40. The assessed Flu strains were: The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

Time frame:
At Day 1 and 1 month after FLU vaccine dose administration (Day 31 for both groups)
Reported as:
Number · Percentage of participants
HI Seroprotection Rate (SPR) for 4 FLU Vaccine Strains
Percentage of participantsCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N2, Day 117.9 (14.7 to 21.6)21.9 (18.3 to 25.7)
Flu A/Darwin/6/2021 H3N2, Day 3175.3 (71.1 to 79.2)76.6 (72.3 to 80.5)
Flu A/Victoria/2570/2019 H1N1, Day 153.4 (48.9 to 57.8)61.0 (56.6 to 65.3)
Flu A/Victoria/2570/2019 H1N1, Day 3192.3 (89.5 to 94.6)94.5 (92.0 to 96.5)
Flu B/Austria/1359417/2021 Victoria, Day 198.8 (97.4 to 99.6)99.6 (98.6 to 100.0)
Flu B/Austria/1359417/2021 Victoria, Day 31100 (99.2 to 100)100 (99.2 to 100)
Flu B/Phuket/3073/2013 Yamagata, Day 196.8 (94.9 to 98.2)98.2 (96.6 to 99.2)
Flu B/Phuket/3073/2013 Yamagata, Day 31100 (99.2 to 100)100 (99.2 to 100)
SecondaryHI Titers for 4 FLU Vaccine Strains, Expressed as MGI

MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

Time frame:
At 1 month after the FLU vaccine dose administration (Day 31 for both groups)
Reported as:
Geometric mean · Ratio
HI Titers for 4 FLU Vaccine Strains, Expressed as MGI
RatioCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N26.20 (5.49 to 7.00)5.87 (5.20 to 6.62)
Flu A/Victoria/2570/2019 H1N15.57 (4.81 to 6.46)4.53 (3.94 to 5.21)
Flu B/Austria/1359417/2021 Victoria2.92 (2.69 to 3.18)2.71 (2.51 to 2.93)
Flu B/Phuket/3073/2013 Yamagata3.13 (2.85 to 3.44)2.87 (2.62 to 3.14)
SecondaryPercentage of Participants With Solicited Administration Site Events After Each Vaccine Dose Administration

The solicited administration site events after vaccination included erythema, pain and swelling.

Time frame:
Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination (administered on Day 1 and 31)
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Administration Site Events After Each Vaccine Dose Administration
Percentage of participantsCo-Ad GroupControl Group
Erythema, Flu administration at Day 14.0 (2.4 to 6.4)4.6 (2.8 to 7.1)
Erythema, RSV administration at Day 14.3 (2.5 to 6.6)—
Erythema, RSV administration at Day 31—4.3 (2.5 to 6.7)
Pain, Flu administration at Day 147.0 (42.2 to 51.9)43.5 (37.7 to 47.4)
Pain, RSV administration at Day 155.6 (50.7 to 60.4)—
Pain, RSV administration at Day 31—45.8 (40.8 to 50.8)
Swelling, Flu administration at Day 14.5 (2.7 to 6.9)5.6 (3.6 to 8.2)
Swelling, RSV administration at Day 14.0 (2.4 to 6.4)—
Swelling, RSV administration at Day 31—4.3 (2.5 to 6.7)
SecondaryPercentage of Participants Reporting Each Solicited Systemic Event After Each Vaccine Dose Administration

The solicited systemic events after vaccination include arthralgia, fatigue, fever, headache and myalgia.

Time frame:
Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination (administered on Day 1 and 31)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Each Solicited Systemic Event After Each Vaccine Dose Administration
Percentage of participantsCo-Ad GroupControl Group
Arthralgia, Dosing at Day 116.1 (12.7 to 19.9)13.8 (10.6 to 15.5)
Arthralgia, Dosing at Day 31—13.0 (9.9 to 16.7)
Fatigue, Dosing at Day 130.5 (26.1 to 35.1)22.0 (18.1 to 26.3)
Fatigue, Dosing at Day 31—23.5 (19.4 to 28.0)
Fever, Dosing at Day 12.1 (1.0 to 4.0)0.7 (0.1 to 2.1)
Fever, Dosing at Day 31—2.0 (0.9 to 3.9)
Headache, Dosing at Day 124.3 (20.3 to 28.7)17.1 (13.6 to 21.1)
Headache, Dosing at Day 31—19.0 (15.3 to 23.2)
Myalgia, Dosing at Day 140.2 (35.5 to 45.0)34.1 (29.5 to 38.8)
Myalgia, Dosing at Day 31—31.3 (26.7 to 36.0)
SecondaryPercentage of Participants Reporting Unsolicited Adverse Events (AEs)

An unsolicited AEs is an AE that is not included in a list of solicited events using a participant diary. Unsolicited events must have been spontaneously communicated by a participant who signs the informed consent. Unsolicited AEs include both serious, non-serious AEs and potential immune-mediated diseases (pIMDs).

Time frame:
Within 30 days after vaccine administration (the day of vaccination and 29 subsequent days after vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Unsolicited Adverse Events (AEs)
Percentage of participantsCo-Ad GroupControl Group
Percentage of Participants Reporting Unsolicited Adverse Events (AEs)12.2 (9.5 to 15.3)13.5 (10.6 to 16.7)
SecondaryPercentage of Participants Reporting Serious Adverse Events (SAEs)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant.

Time frame:
From Day 1 up to study end (6 months after last vaccination - Month 6 for Co-Ad Group and Month 7 for Control group)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events (SAEs)
Percentage of participantsCo-Ad GroupControl Group
Percentage of Participants Reporting Serious Adverse Events (SAEs)2.3 (1.2 to 4.0)2.9 (1.6 to 4.8)
SecondaryPercentage of Participants Reporting Potential Immune-mediated Disease (pIMDs)

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. The investigator must exercise his/her medical/scientific judgment to determine whether other diseases have an autoimmune origin (i.e. pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and should also be recorded as a pIMD.

Time frame:
From Day 1 up to study end (6 months after last vaccination - Month 6 for Co-Ad Group and Month 7 for Control group)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Potential Immune-mediated Disease (pIMDs)
Percentage of participantsCo-Ad GroupControl Group
Percentage of Participants Reporting Potential Immune-mediated Disease (pIMDs)0 (0 to 0.7)0.4 (0.0 to 1.4)

Adverse events

Collected over Solicited AEs were collected during 4-day follow-up period after each vaccination. Unsolicited AEs were collected during 30-day follow-up period after each vaccination. SAEs and pIMDs were collected throughout the study period (from Day 1 to study end [6 months after last vaccination]).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Co-Ad Group1/516 (0.2%)12/516 (2.3%)339/516 (65.7%)
Control Group0/513 (0%)15/513 (2.9%)319/513 (62.2%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCo-Ad GroupControl Group
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/5161/513
COVID-19Infections and infestations0/5161/513
Diverticulitis intestinal haemorrhagicInfections and infestations0/5161/513
GastroenteritisInfections and infestations0/5161/513
Pneumonia respiratory syncytial viralInfections and infestations0/5161/513
Spinal cord infectionInfections and infestations0/5161/513
Cardiac failure congestiveCardiac disorders1/5161/513
Angina unstableCardiac disorders0/5161/513
Arteriosclerosis coronary arteryCardiac disorders0/5161/513
Sinus node dysfunctionCardiac disorders0/5161/513
Most frequent other events
Showing 10 of 106
Most frequent other events
EventCo-Ad GroupControl Group
Injection site painGeneral disorders273/516257/513
MyalgiaMusculoskeletal and connective tissue disorders177/516203/513
FatigueGeneral disorders130/516140/513
HeadacheNervous system disorders113/516128/513
ArthralgiaMusculoskeletal and connective tissue disorders73/51691/513
Injection site swellingGeneral disorders27/51634/513
Injection site erythemaGeneral disorders27/51634/513
PyrexiaGeneral disorders11/51613/513
COVID-19Infections and infestations2/51610/513
CoughRespiratory, thoracic and mediastinal disorders2/5167/513

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Co-Ad GroupControl GroupTotal
Mean71.3 ± 5.371.1 ± 5.171.2 ± 5.2
Sex: Female, Male
Sex: Female, Male(Participants)Co-Ad GroupControl GroupTotal
Female267243510
Male249270519
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Co-Ad GroupControl GroupTotal
American Indian or Alasaka Native4610
Asian448
Black or African American7268140
Native Hawaiian or Other Pacific Islander011
White355352707
Other, Not Specified8182163
08

Study locations

46 sites
  • GSK Investigational Site
    Birmingham, Alabama 35205, United States
  • GSK Investigational Site
    Tempe, Arizona 85281, United States
  • GSK Investigational Site
    Canoga Park, California 91303, United States
  • GSK Investigational Site
    Colton, California 92324, United States
  • GSK Investigational Site
    Sacramento, California 95864, United States
  • GSK Investigational Site
    San Diego, California 92103-6204, United States
  • GSK Investigational Site
    Walnut Creek, California 94598, United States
  • GSK Investigational Site
    Aurora, Colorado 80012, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Fort Myers, Florida 33912, United States
  • GSK Investigational Site
    Hialeah, Florida 33012, United States
  • GSK Investigational Site
    Immokalee, Florida 34142, United States
  • GSK Investigational Site
    Miami, Florida 33016, United States
  • GSK Investigational Site
    Miami, Florida 33184, United States
  • GSK Investigational Site
    Orlando, Florida 32801, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Sandy Springs, Georgia 30328, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Chicago, Illinois 60640, United States
  • GSK Investigational Site
    Evansville, Indiana 47714, United States
  • GSK Investigational Site
    Mishawaka, Indiana 46544, United States
  • GSK Investigational Site
    Valparaiso, Indiana 46383, United States
  • GSK Investigational Site
    Ames, Iowa 50010, United States
  • GSK Investigational Site
    El Dorado, Kansas 67042, United States
  • GSK Investigational Site
    Methuen, Massachusetts 01844, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Grand Island, Nebraska 68803, United States
  • GSK Investigational Site
    Papillion, Nebraska 68046, United States
  • GSK Investigational Site
    North Las Vegas, Nevada 89030, United States
  • GSK Investigational Site
    Warren, New Jersey 07059, United States
  • GSK Investigational Site
    Hickory, North Carolina 28601, United States
  • GSK Investigational Site
    Rocky Mount, North Carolina 27804, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45236, United States
  • GSK Investigational Site
    Edmond, Oklahoma 73013, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15243, United States
  • GSK Investigational Site
    Columbia, South Carolina 21045, United States
  • GSK Investigational Site
    North Charleston, South Carolina 29405, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Jefferson City, Tennessee 37760, United States
  • GSK Investigational Site
    Memphis, Tennessee 38119, United States
  • GSK Investigational Site
    Nashville, Tennessee 37912, United States
  • GSK Investigational Site
    Austin, Texas 78745, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    San Antonio, Texas 78237, United States
09

References and documents

Publications

  • Buynak R, Cannon K, DeAtkine D, Kirby J, Usdan L, Bhavsar A, Gerard C, Kuznetsova A, Jayadev A, Amare H, Valenciano S, Meyer N. Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged >/= 65. Infect Dis Ther. 2024 Aug;13(8):1789-1805. doi: 10.1007/s40121-024-00985-4. Epub 2024 Jun 26. PubMed 38981954 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Mar 2023, 4 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 4 months is below that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Sep 29, 2022
StartActual
Oct 20, 2022
Primary completionActual
Mar 7, 2023
CompletionActual
Aug 15, 2023
Results first posted
Apr 4, 2024
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05559476
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 29, 2022
Start date
Oct 20, 2022
Primary completion
Mar 7, 2023
Completion
Aug 15, 2023
Results posted
Apr 4, 2024
Last update
Sep 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion